Yeji
FDA approvalconf 0.70

FDA approval

$AXSM · Axsome Therapeutics, Inc.
Event date
Date TBD
Sponsor runway
44 mo
$305.1M liquid

Evidence

“a dual-acting dopamine and norepinephrine reuptake inhibitor indicated to improve wakefulness in adult patients living with excessive daytime sleepiness due to narcolepsy or obstructive sleep apnea, which was approved by the U.S. Food and Drug Administration ("FDA") in 2019”
Source: 8-K filed 2022-03-28View on EDGAR ↗0000950170-22-004722

Comparable historical fda approvals· last 5 years · same event type

100% hit rate (10/10)
TickerDrugDateOutcome
$INCYzynyz2026-05-18success
$INCYjakafi xr2026-05-01success
$AXSMauvelity2026-04-30success
$INCYzynyz2026-03-30success
$BIIBspinraza2026-03-27success
$CORTlifyorli2026-03-25success
$RYTMimcivree2026-03-19success
$ASNDyuviwel2026-02-27success
$BMRNpalynziq2026-02-27success
$ETONdesmoda2026-02-25success

Recent insider activity· ±90 days

5 insiders · 0 buys · 3 sells
Exercise10b5-1
2026-05-05
Jacobson Mark L.
Chief Operating Officer
233 @ $12.95$3K
Sell10b5-1
2026-05-05
Jacobson Mark L.
Chief Operating Officer
233 @ $228.18$53K
Sell10b5-1
2026-05-04
Jacobson Mark L.
Chief Operating Officer
4,517 @ $227.94$1.03M
Exercise10b5-1
2026-05-04
Jacobson Mark L.
Chief Operating Officer
4,517 @ $12.95$58K
Exercise10b5-1
2026-04-22
Maizel Ari
Chief Commercial Officer
7,500 @ $70.73$530K
Sell10b5-1
2026-04-22
Maizel Ari
Chief Commercial Officer
7,500 @ $182.42$1.37M
Grant
2026-04-21
TABUTEAU HERRIOT
Chief Executive Officer
24,081 @ ——
Grant
2026-04-21
Maizel Ari
Chief Commercial Officer
7,224 @ ——
Grant
2026-04-21
Jacobson Mark L.
Chief Operating Officer
8,669 @ ——
Grant
2026-04-21
Murdock Hunter R.
General Counsel
7,224 @ ——
Grant
2026-04-21
Pizzie Nick
Chief Financial Officer
8,188 @ ——
← All catalysts for $AXSM